EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Characterizing prostate zonal shape changes associated with 5α‐reductase inhibitors using MRI

Alper Vatansever, Melih Yetemen, Gökhan Öngen, Gökhan Ocakoğlu, Burhan Coşkun

Clinical Anatomy · 2024

DOI: 10.1002/ca.24218 ↗

At a glance

Journal article in Clinical Anatomy, 2024. Written by Alper Vatansever and 4 co-authors. Institution: Department of Anatomy, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye. Major MEDLINE topics: 5-alpha Reductase Inhibitors, Prostatic Hyperplasia, Magnetic Resonance Imaging, Prostate. Cited 3 times so far (Crossref); 16 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Benign prostatic hyperplasia (BPH) is a prevalent medical disorder that primarily affects elderly males. It is distinguished by enhanced angiogenesis of the prostate, aggravating lower urinary tract symptoms (LUTS) and diminishing overall quality of life. Dutasteride, a 5α‐reductase inhibitor, has emerged as a significant therapeutic choice for BPH owing to its efficacy in reducing prostate volume. The objective of this study is to analyze alterations in the shapes of prostate zones resulting from dutasteride treatment of BPH, using MRI. We examined 19 drug‐administered patients and 33 non‐drug‐administered patients. MRI sections of all participants before and after drug treatment were collected retrospectively. The transition zone and peripheral zone of the prostate were marked with selected landmarks using TPSDIG v2.04. Generalized Procrustes Analysis was used to analyze shapes statistically. Our results showed that the 5α‐reductase inhibitor significantly altered the shape of the transition zone by narrowing its posterior part. There were significant statistical differences between the drug‐administered and non‐drug‐administered groups in the initial and final shapes of the transition zone. These findings indicate that the use of 5α‐reductase inhibitors yielded favorable outcomes in terms of prostate size reduction and amelioration of symptoms associated with BPH.

Subjects

MeSH terms (MEDLINE)

5-alpha Reductase InhibitorsProstatic HyperplasiaMagnetic Resonance ImagingProstateDutasterideHumansMaleAgedRetrospective StudiesMiddle AgedAged, 80 and over

Author keywords

5α‐reductase inhibitorsBPHMRIanatomybenign prostatic hyperplasiacancermalignancyshape analysisurology

Substances

5-alpha Reductase InhibitorsDutasteride

Authors and institutions

  • Department of Anatomy, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.
  • Department of Urology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.
  • Department of Radiology, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.
  • Department of Biostatistics, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye.

Cite

APA

Vatansever, A., Yetemen, M., Öngen, G., Ocakoğlu, G., & Coşkun, B. (2024). Characterizing prostate zonal shape changes associated with 5α‐reductase inhibitors using MRI. Clinical Anatomy. https://doi.org/10.1002/ca.24218

Vancouver

Vatansever A, Yetemen M, Öngen G, Ocakoğlu G, Coşkun B. Characterizing prostate zonal shape changes associated with 5α‐reductase inhibitors using MRI. Clinical Anatomy. 2024. doi:10.1002/ca.24218

BibTeX
@article{Vatansever2024,
  author = {Vatansever, Alper and Yetemen, Melih and Öngen, Gökhan and Ocakoğlu, Gökhan and Coşkun, Burhan},
  title = {Characterizing prostate zonal shape changes associated with 5α‐reductase inhibitors using MRI},
  journal = {Clinical Anatomy},
  year = {2024},
  doi = {10.1002/ca.24218}
}
Start for free →